Armis and TrueFort Announce Strategic Partnership
12.4.2023 15:00:00 EEST | Business Wire | Press release
Armis, the leading asset visibility and security company, today announced a strategic partnership and integration with TrueFort, the lateral movement protection company. This collaboration empowers customers by enriching the discovery, understanding, and enforcement of security policies for IT, Internet of Things (IoT), and operational technology (OT) environments.
“Customers have shared with us just how critical context is for them when it comes to understanding how applications are connected to specific assets, who owns these applications, and how important they are to the business,” said Brian Gumbel, President, Armis. “This partnership with TrueFort enables us to put in place better security and segmentation policies to increase operational resilience and we are pleased to bring our combined expertise to customers.”
Research has found that lateral movement is used in 60% of all attacks. This is a result of OT and IT environments typically being combined into one flat network. If security teams do not have full visibility here, malicious actors can target both environments and move undetected between the two.
“Enterprises today have a great challenge to identify, document, map, and separate applications in a secure and controlled way with high accuracy and integrity,” said Sameer Malhotra, CEO and Co-founder, TrueFort. “This is especially true in critical industries, such as manufacturing, utilities, healthcare, and financial services. Together, Armis and TrueFort can fully discover and map IT and OT environments to enforce intelligent policies that prevent unauthorized lateral movement.”
Together, TrueFort and Armis help customers to:
- Discover all connected assets on the network, including applications, devices, service accounts, and infrastructure within a day using existing agent and agentless technology.
- Understand workload behavior and map it to the applications to baseline normal operations, empowering users with full confidence in what to block, disable, and kill.
- Enforce by account and action or push enforcement to host firewalls with the TrueFort or existing EDR agent.
“It’s critical that we operate securely in order to focus on our core mission: to bring efficient and sustainable climate solutions to buildings, homes, and transportation,” said James Powell, CISO, Trane Technologies. “Armis and TrueFort individually have been tremendous partners to us, so as a customer of both, this collaboration and the extended capabilities and services we’ll benefit from are exciting.”
The RSA Conference 2023 theme this year is, Stronger Together. The TrueFort and Armis partnership embodies this sentiment. This year at the event, both organizations will come together for a joint presentation. To attend, please visit Armis booth S-1127 on Tuesday, April 25, 2023 at 2:00pm PT. To learn more about Armis at RSA Conference, please visit: https://www.armis.com/rsac-2023/
TrueFort is a member of the Armis Partner Experience (APEX) program. The mission of this program is to build long-term, strategic relationships between Armis and its partners, and to foster collaboration to serve customers in the best way possible. Apply here to become a partner.
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
About TrueFort
TrueFort puts you in control of lateral movement across the data center and cloud. The TrueFort Cloud extends protection beyond network activity by shutting down the abuse of service accounts. Founded by former IT executives from Bank of America and Goldman Sachs, leading global enterprises trust TrueFort to deliver unmatched application environment discovery and microsegmentation for both identity and activity. For more information visit https://truefort.com and follow us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230412005062/en/
Contact information
Media Contacts:
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
Marc Gendron
Marc Gendron PR for TrueFort
marc@mgpr.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom